Table II.
Associations between the V600E BRAF and clinicopathologic features of papillary thyroid cancer
| BRAF-positive | BRAF-negative | ||
|---|---|---|---|
| Clinicopathologic | n = 44 (70%) | n = 19 (30%) | |
| features | n (%) | n (%) | P value |
| Gender | |||
| Female | 34 (77) | 16 (84) | .532 |
| Male | 10 (23) | 3 (16) | |
| Age (yrs) | |||
| <45 | 21 (48) | 9 (47) | .979 |
| ≥45 | 23 (52) | 10 (53) | |
| Race | |||
| White | 38 (86) | 12 (63) | .037* |
| Non-white | 6 (14) | 7 (37) | |
| Tumor size (cm) | |||
| <2 | 25 (57) | 13 (68) | .388 |
| ≥2 | 19 (43) | 6 (32) | |
| Multifocality | |||
| No | 27 (61) | 8 (42) | .158 |
| Yes | 17 (39) | 11 (58) | |
| Variant | |||
| Conventional | 40 (90) | 16 (84) | .218 |
| Follicular | 2 (5) | 3 (16) | |
| Tall cell | 2 (5) | 0 | |
| Venous/lymphatic invasion | |||
| Absent | 20 (45) | 13 (68) | .094 |
| Present | 24 (55) | 6 (32) | |
| Surgical margins | |||
| Negative | 36 (82) | 15 (79) | .790 |
| Positive | 8 (18) | 4 (21) | |
| Central lymph node metastasis | |||
| Absent | 15 (34) | 10 (53) | .167 |
| Present | 29 (66) | 9 (47) | |
| Extrathyroid extension | |||
| Absent | 39 (89) | 18 (95) | .449 |
| Present | 5 (11) | 1 (5) | |
| AJCC stage | |||
| I + II | 27 (61) | 15 (79) | .174 |
| III + IV | 17 (39) | 4 (21) |
*
Statistically significant.
AJCC, American Joint Committee on Cancer.